NCT07681050 Phosphate in Acute Pancreatitis
| NCT ID | NCT07681050 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Duke University |
| Condition | Pancreatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-07-09 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2026-07-09 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn if phosphate administration works to treat acute pancreatitis in adults presenting to the emergency department at Duke University Hospital. The main questions it aims to answer are: * Does having low phosphate levels increase the risk of acute pancreatitis and can giving phosphate through an IV make the illness less severe? * Is phosphate therapy practical to use, and what is the appropriate dose? * Is this study achievable, and how can the results help design a future randomized controlled trial to assess safety and effectiveness? Participants will: * Receive standard of care or intravenous (IV) phosphate during their hospital stay * Have blood samples collected during admission to monitor phosphorus levels * Complete follow-up assessments after hospital admission to evaluate how severe the illness is and the effects of phosphate supplementation
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Presenting to the emergency department (ED) with acute pancreatitis meeting 2 or more characteristics of: (1) typical, persistent, severe upper abdominal pain, (2) lipase or amylase levels at least three times greater than the upper limit of normal, and/or (3) characteristic findings on abdominal imaging) * Trial treatment can be initiated within 24 hours of hospital admission * Consent can be obtained from the patient or their legal representative Exclusion Criteria: Contraindications to injectable phosphate including: * Hyperkalemia * Hypercalcemia or significant hypocalcemia * Severe renal impairment (eGFR \<30 mL/min/1.73m2) or end-stage renal disease
Contact & Investigator
Samuel Francis, MD
PRINCIPAL INVESTIGATOR
Duke University Hospital
Frequently Asked Questions
Who can join the NCT07681050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07681050 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07681050 currently recruiting?
Yes, NCT07681050 is actively recruiting participants. Contact the research team at samuel.francis@duke.edu for enrollment information.
Where is the NCT07681050 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT07681050 clinical trial?
NCT07681050 is sponsored by Duke University. The principal investigator is Samuel Francis, MD at Duke University Hospital. The trial plans to enroll 100 participants.